Placing of 50,000,000 New Ordinary Shares and Warrants

Placing of 50,000,000 New Ordinary Shares and Warrants
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.
Sub-contract approach for VISITECT® COVID-19 antigen test
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products announces that it has successfully CE marked its VISITECT®
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that Colin King, Chief Executive Officer, has notified the Board that
VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, provides an update in relation to the Company’s contract
Omega Diagnostics, a medical testing company, has reported greater interim losses despite an increase in revenues.